Edition:
United States

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

139.77USD
17 Aug 2018
Change (% chg)

$0.38 (+0.27%)
Prev Close
$139.39
Open
$139.39
Day's High
$140.21
Day's Low
$137.93
Volume
284,104
Avg. Vol
313,406
52-wk High
$156.82
52-wk Low
$100.20

Select another date:

Tue, May 22 2018

BRIEF-Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards Sapien 3 Valve

* REAL-WORLD EVIDENCE CONFIRMS CLINICAL TRIAL OUTCOMES FOR PATIENTS TREATED WITH EDWARDS SAPIEN 3 VALVE

BRIEF-Edwards Lifesciences Enters Into Accelerated Share Repurchase Agreement

* EDWARDS LIFESCIENCES ENTERS INTO ACCELERATED SHARE REPURCHASE AGREEMENT

BRIEF-Edwards Lifesciences Says Entered Into Credit Agreement To Establish Multi-Currency Unsecured Revolving Credit Facility - SEC Filing

* EDWARDS LIFESCIENCES SAYS ENTERED INTO CREDIT AGREEMENT TO ESTABLISH NEW 5-YEAR $750 MILLION MULTI-CURRENCY UNSECURED REVOLVING CREDIT FACILITY - SEC FILING

BRIEF-Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy

* EDWARDS GRANTED CE MARK FOR FIRST TRANSCATHETER TRICUSPID THERAPY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Edward Lifesciences' heart valve sales in Europe disappoint, shares fall

Edwards Lifesciences Corp's first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc .

UPDATE 2-Edward Lifesciences' heart valve sales in Europe disappoint, shares fall

April 24 Edwards Lifesciences Corp's first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc.

BRIEF-Edwards Lifesciences Reports Q1 Earnings Of $0.96/Share

* QUARTERLY TOTAL ADJUSTED SALES $937.5 MILLION, UP 9.3 PERCENT

Edwards Lifesciences reports 1.3 pct rise in quarterly sales

April 24 Medical device maker Edwards Lifesciences Corp reported a 1.3 percent rise in first-quarter revenue on Tuesday on higher demand for transcatheter heart valves, its biggest business.

BRIEF-Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences

* BOSTON SCIENTIFIC PREVAILS IN EUROPEAN PATENT DISPUTE WITH EDWARDS LIFESCIENCES

BRIEF-Edwards Lifesciences Corp Says CEO Michael Mussallem's FY 2017 Total Compensation Was $10.8 Mln Vs $9.7 Mln In FY 2016

* EDWARDS LIFESCIENCES CORP SAYS CEO MICHAEL MUSSALLEM'S FY 2017 TOTAL COMPENSATION WAS $10.8 MILLION VERSUS $9.7 MILLION IN FY 2016 - SEC FILING Source text: (https://bit.ly/2GUuNcF) Further company coverage:

Select another date: